Targeting Neurogenesis in Seeking Novel Treatments for Ischemic Stroke

The interruption of cerebral blood flow leads to ischemic cell death and results in ischemic stroke. Although ischemic stroke is one of the most important causes of long-term disability and mortality, limited treatments are available for functional recovery. Therefore, extensive research has been conducted to identify novel treatments. Neurogenesis is regarded as a fundamental mechanism of neural plasticity. Therefore, therapeutic strategies targeting neurogenesis are thought to be promising. Basic research has found that therapeutic intervention including cell therapy, rehabilitation, and pharmacotherapy increased neurogenesis and was accompanied by functional recovery after ischemic stroke. In this review, we consolidated the current knowledge of the relationship between neurogenesis and treatment for ischemic stroke. It revealed that many treatments for ischemic stroke, including clinical and preclinical ones, have enhanced brain repair and functional recovery post-stroke along with neurogenesis. However, the intricate mechanisms of neurogenesis and its impact on stroke recovery remain areas of extensive research, with numerous factors and pathways involved. Understanding neurogenesis will lead to more effective stroke treatments, benefiting not only stroke patients but also those with other neurological disorders. Further research is essential to bridge the gap between preclinical discoveries and clinical implementation.

Medienart:

E-Artikel

Erscheinungsjahr:

2023

Erschienen:

2023

Enthalten in:

Zur Gesamtaufnahme - volume:11

Enthalten in:

Biomedicines - 11(2023), 10 vom: 13. Okt.

Sprache:

Englisch

Beteiligte Personen:

Nagase, Takayuki [VerfasserIn]
Kin, Kyohei [VerfasserIn]
Yasuhara, Takao [VerfasserIn]

Links:

Volltext

Themen:

Cell therapy
Ischemic stroke
Journal Article
Neurogenesis
Rehabilitations
Review

Anmerkungen:

Date Revised 30.10.2023

published: Electronic

Citation Status PubMed-not-MEDLINE

doi:

10.3390/biomedicines11102773

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM36385164X